Loading...
|
Please use this identifier to cite or link to this item:
http://ir.nhri.org.tw/handle/3990099045/14798
|
| Title: | Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma |
| Authors: | Goyal, L;Meric-Bernstam, F;Hollebecque, A;Valle, JW;Morizane, C;Karasic, TB;Abrams, TA;Furuse, J;Kelley, RK;Cassier, PA;Klümpen, HJ;Chang, HM;Chen, LT;Tabernero, J;Oh, DY;Mahipal, A;Moehler, M;Mitchell, EP;Komatsu, Y;Masuda, K;Ahn, D;Epstein, RS;Halim, AB;Fu, Y;Salimi, T;Wacheck, V;He, Y;Liu, M;Benhadji, KA;Bridgewater, JA |
| Contributors: | National Institute of Cancer Research |
| Abstract: | BACKGROUND: Alterations in fibroblast growth factor receptor 2 (FGFR2) have emerged as promising drug targets for intrahepatic cholangiocarcinoma, a rare cancer with a poor prognosis. Futibatinib, a next-generation, covalently binding FGFR1-4 inhibitor, has been shown to have both antitumor activity in patients with FGFR-altered tumors and strong preclinical activity against acquired resistance mutations associated with ATP-competitive FGFR inhibitors. METHODS: In this multinational, open-label, single-group, phase 2 study, we enrolled patients with unresectable or metastatic FGFR2 fusion-positive or FGFR2 rearrangement-positive intrahepatic cholangiocarcinoma and disease progression after one or more previous lines of systemic therapy (excluding FGFR inhibitors). The patients received oral futibatinib at a dose of 20 mg once daily in a continuous regimen. The primary end point was objective response (partial or complete response), as assessed by independent central review. Secondary end points included the response duration, progression-free and overall survival, safety, and patient-reported outcomes. RESULTS: Between April 16, 2018, and November 29, 2019, a total of 103 patients were enrolled and received futibatinib. A total of 43 of 103 patients (42%; 95% confidence interval, 32 to 52) had a response, and the median duration of response was 9.7 months. Responses were consistent across patient subgroups, including patients with heavily pretreated disease, older adults, and patients who had co-occurring TP53 mutations. At a median follow-up of 17.1 months, the median progression-free survival was 9.0 months and overall survival was 21.7 months. Common treatment-related grade 3 adverse events were hyperphosphatemia (in 30% of the patients), an increased aspartate aminotransferase level (in 7%), stomatitis (in 6%), and fatigue (in 6%). Treatment-related adverse events led to permanent discontinuation of futibatinib in 2% of the patients. No treatment-related deaths occurred. Quality of life was maintained throughout treatment. CONCLUSIONS: In previously treated patients with FGFR2 fusion or rearrangement-positive intrahepatic cholangiocarcinoma, the use of futibatinib, a covalent FGFR inhibitor, led to measurable clinical benefit. (Funded by Taiho Oncology and Taiho Pharmaceutical; FOENIX-CCA2 ClinicalTrials.gov number, NCT02052778.). |
| Date: | 2023-01-19 |
| Relation: | New England Journal of Medicine. 2023 Jan 19;388(3):228-239. |
| Link to: | http://dx.doi.org/10.1056/NEJMoa2206834 |
| JIF/Ranking 2023: | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0028-4793&DestApp=IC2JCR |
| Cited Times(WOS): | https://www.webofscience.com/wos/woscc/full-record/WOS:000926442300004 |
| Cited Times(Scopus): | https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85149023684 |
| Appears in Collections: | [陳立宗] 期刊論文
|
Files in This Item:
| File |
Description |
Size | Format | |
|---|
| PUB36652354.pdf | | 709Kb | Adobe PDF | 176 | View/Open |
|
All items in NHRI are protected by copyright, with all rights reserved.
|
